Orgenesis Inc. Faces Nasdaq Delisting, Shifts to OTC Markets
Orgenesis Inc. Faces Nasdaq Delisting
Orgenesis Inc. has recently announced significant changes as it transitions from Nasdaq to OTC Markets. This decision comes after the company received a formal notification from Nasdaq Stock Market, indicating that its common stock would be delisted. This move stems from the conclusion of a review by the Nasdaq Hearings Panel which found that Orgenesis did not meet the necessary requirements for continued listing.
Reasons for Delisting
The decision to delist was influenced primarily by Orgenesis' failure to adhere to the minimum bid price requirement, as well as failing to meet the minimum stockholders’ equity requirements. Despite a strategic move involving a reverse stock split intended to help regain compliance, the company fell short. This reverse stock split, which occurred shortly before the delisting notification, brought down the total number of shares from approximately 47.7 million to 4.77 million.
Transition to OTC Markets
As trading on Nasdaq ceases, Orgenesis' stock is anticipated to begin trading on the OTC Markets under the ticker symbol 'ORGS'. This transformation marks a significant shift in the company's market presence. In a bid to improve its standing, Orgenesis has also applied to be quoted on the OTCQX, a more prestigious category within the OTC markets that prides itself on housing companies that fulfill stricter financial criteria.
Corporate Developments
Despite these challenges, Orgenesis is striving to ensure compliance with regulatory standards and intends to continue regular reporting to the U.S. Securities and Exchange Commission. The company remains committed to maintaining investor confidence and compliance throughout this transition.
Encouraging Therapy Results
In the midst of operational hurdles, Orgenesis has reported positive developments regarding its CD19 CAR-T therapy, known as ORG-101. This innovative treatment has demonstrated promising results in clinical trials for Acute Lymphoblastic Leukemia, showcasing high response rates among both adults and children. Such progress offers a glimmer of hope for the company as it navigates through a turbulent financial period.
Financial Challenges and Future Outlook
Financially, Orgenesis faced hefty challenges leading to the Nasdaq delisting. Publicly available data highlights the company's market capitalization, now sitting at $15.36 million, which categorizes it as a small-cap entity. Additionally, their reported revenue of $0.66 million over the previous year reflects a troubling decline of nearly 97%. Investors are understandably cautious, given that the company's expense levels are rising amidst a substantial debt burden.
Funding and Collaborations
In an effort to bolster its financial health, Orgenesis has secured a recent funding boost of $750,000 from investor Jacob Safier, bringing the total loan amount to $1 million. This influx of capital is critical for the company as it looks to ensure operational continuity and pursue further innovations.
Moreover, a launched joint venture with Harley Street Healthcare Group marks another significant milestone. This partnership aims to develop and commercialize wellness and longevity therapies on a global scale, with a notable commitment of $10 million over the next three years from HSHG.
Conclusion
While the delisting news presents a major obstacle for Orgenesis Inc., the company is actively pursuing avenues for recovery and growth. Their focus on innovative therapies and strategic partnerships highlights a commitment to overcoming current challenges. Investors and stakeholders should remain informed of the company’s progress as it continues to adapt to its new trading environment.
Frequently Asked Questions
What is the reason for Orgenesis Inc. being delisted from Nasdaq?
Orgenesis Inc. was delisted due to its inability to meet Nasdaq’s minimum bid price and stockholders’ equity requirements.
What will happen to Orgenesis’ stock after the delisting?
The company's stock will begin trading on the OTC Markets under the same ticker symbol 'ORGS'.
How is Orgenesis addressing its financial challenges?
Orgenesis has secured additional funding and is pursuing strategic partnerships to enhance its financial standing and support its ongoing operations.
What is the CD19 CAR-T therapy developed by Orgenesis?
CD19 CAR-T therapy, referred to as ORG-101, is an innovative treatment aimed at treating Acute Lymphoblastic Leukemia.
What steps is Orgenesis taking to comply with regulatory standards?
Orgenesis is committed to submitting periodic reports to the U.S. Securities and Exchange Commission to maintain compliance with regulatory standards.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Investigating Investor Claims Against Progyny: Impact Analysis
- Investigation into Vanda Pharmaceuticals Inc. Sparks Concerns
- Investigation Launched into Visa Inc. Practices Amid Antitrust Claims
- Kaspi.kz Investors Urged to Explore Securities Fraud Claims
- Investigation Launched Into 2seventy Bio, Inc. Securities Claims
- Investigation Launched for Winnebago Industries Investors
- Investigation Launched for Light & Wonder, Inc. Shareholders
- Investigation Launched for Applied Materials Investors Amid Claims
- Investigating Claims Against Laser Photonics Corp. – LASE
- WM Technology Investors Targeted in Class Action Suit Claims
Recent Articles
- Autonomix Medical Secures New Auditor and Stock Split Approval
- Bitech Technologies Announces Board Expansion and New Deal
- Vizsla Silver Expands Portfolio with La Garra-Metates Acquisition
- China's Economic Future: Transitioning from Exports to Consumption
- Central Bank of Chile Lowers Rates to Encourage Growth
- Challenges Faced by Russian Stocks as MOEX Sees Declines
- Colombia Stock Market Sees Positive Gains with COLCAP Rise
- Mexico Stock Market Update: S&P/BMV IPC Sees Minor Decline
- EVERTEC Announces Consistent Quarterly Dividend for Shareholders
- Telix Pharmaceuticals Moves Forward with Nasdaq Listing Plans
- Monroe Federal Bancorp, Inc. Readies for Significant IPO Event
- GPM Initiates Investigation into CSX Corporation's Practices
- PIMCO Canada Corp. Updates Monthly ETF Distributions
- Understanding the Upcoming iShares iBonds ETF Liquidations
- New CPKC and CSX Connection to Enhance Rail Networks
- Investigation Launched into CSX Corporation for Investor Protection
- Baylin Technologies Enhances Connectivity with New Antennas
- Spheric Assurance Company Maintains Strong Ratings Amid Challenges
- Exciting Leadership Transition at b1BANK with Jerry Vascocu
- Revolutionizing Lawn Care: Verde.Ai Launches R-1000 Mower
- Understanding the Growth of a $1000 Investment in Targa Resources
- Flaherty & Crumrine Funds Reveal Upcoming November Distributions
- Vizsla Silver Completes Strategic Acquisition to Boost Projects
- Potential Changes Looming for Google's Deals with Apple iPhones
- Colabor Group's Third Quarter Results Showcase Resilience
- Justin Bird Honored as Energy Leader of the Year by Industry Peers
- Growth of Autonomous Mobile Robots Market Driven by AI and ROI
- PNM Grid Modernization Initiative Approved for a Sustainable Future
- Booming Massage Equipment Market Set for Major Growth Ahead
- Delightful Halloween Treats Await at It's Boba Time!
- Future of Wound Care Market: Growth Prospects and Innovations
- Transformative Rail Connection Approved Enhancing Logistics Network
- Colabor Group's Q3 2024 Financial Results Reveal Challenges Ahead
- b1BANK Elevates Jerry Vascocu to President Position
- Historic $1.5 Billion Settlement Achieved by Mary Alexander & Associates
- Diodes Incorporated to Host Q3 2024 Financial Results Call
- ACM Research Shares Earnings Call Schedule and Insights Ahead
- Life Time Unveils Exciting Prize Purses for 2025 Events
- Upcoming Financial Results Announcement by Sight Sciences
- Investigation Launch for Acadia Healthcare: A Deep Dive
- Join Aware's Upcoming Webcast for Q3 Financial Results
- Granite REIT Announces October 2024 Distribution Details
- New Class I Rail Connection Enhances Trade Pathways in U.S.
- El Pollo Loco Gears Up for Anticipated Q3 2024 Financial Review
- Investors Encouraged to Join Significant iLearningEngines Case
- Brilliant Earth Set to Share Q3 2024 Financial Insights Soon
- Stoneridge, Inc. to Host Third Quarter Earnings Call Live
- Supernus Pharmaceuticals Reports Positive Phase 2a Study Results
- Anterix to Hold Second Quarter Fiscal 2025 Earnings Call
- Breakthrough Properties Celebrates Torrey View Opening with Community Leaders